Skip to content
PeptideAI
Animal data onlyhairskinhealing

Thymosin Beta-4 (cosmetic)

The actin-sequestering repair peptide applied to skin and scalp rather than injected, on the strength of mouse data showing it activates hair follicle stem cells.

Also known as TB4 topical, Tbeta4 hair serum, timbetasin (topical use), RGN-259

Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.

The hair follicle stem cell activation and wound-healing data are mouse and cell-culture work; the only substantial human trials of Tbeta4 are ophthalmic, as RGN-259 eye drops for dry eye and neurotrophic keratopathy. There is no human trial of topical Tbeta4 for hair or facial skin.

How it works

Thymosin beta-4 is the major intracellular G-actin sequestering protein in mammals, which is what lets it govern cytoskeletal reorganisation and therefore cell migration. In mouse skin it activates hair follicle stem cells in the bulge region, promotes their migration and differentiation, and accelerates hair growth alongside its better-known effects on angiogenesis, keratinocyte migration and reduced fibrosis. Applied topically it is used for the same reasons in scalp serums and post-procedure skin protocols. The obvious problem for cosmetic use is size: at nearly 5 kDa this is roughly an order of magnitude larger than anything that reliably crosses intact stratum corneum, so topical use effectively depends on compromised barrier — post-microneedling, post-laser or open wounds.

Targets: G-actin, Hair follicle bulge stem cells, Keratinocyte and endothelial migration, Angiogenesis, Fibrosis reduction

Dosing

ProtocolDoseFrequencyRoute
Post-procedure skin applicationApplied immediately after microneedling, fractional laser or dermabrasion while the barrier is open.—once or twice daily for 5-7 days after the proceduretopical
Anecdotal scalp serumApplied at night, often after dermarolling.—once dailytopical
  • · Typically 0.01-0.05% in a sterile, preservative-free aqueous vehicle. This is the only topical use with a coherent delivery rationale, because intact skin will not admit a 5 kDa peptide.
  • · No validated human protocol. Community use is 0.01-0.05% in a scalp vehicle, with the same penetration caveat.

Cycling

Post-procedure use is a 5-7 day course. Scalp use has no established cycle length.

Work out your exact syringe units →

Pharmacology

Half-life
Not established for topical use; injected Tbeta4 has a plasma half-life of roughly 1-2 hours.
Onset
Post-procedure healing effects within days; any hair effect would require 3-6 months.
Routes
topical, intradermal
Molecule
Endogenous 43-amino-acid actin-sequestering peptide
Sequence length
43 amino acids
Molecular weight
4963.4 Da

Handling

Diluent
Bacteriostatic water for injectable-grade material; sterile water for a preservative-free topical
Typical mix
2 or 5 mL
Vial sizes
2, 5, 10 mg
Lyophilised
Refrigerated or frozen, sealed and dry.
Reconstituted
Refrigerated; use within about 20-30 days.
Light sensitive
Yes — keep it out of the light

Mixing

Aim the stream down the vial wall and swirl gently. Never shake a peptide of this size — you will denature it.

Side effects

  • uncommonApplication-site irritation on compromised skin
  • rareTheoretical concern about promoting growth of existing lesions— Tbeta4 is pro-angiogenic and pro-migratory; those are not qualities you want near an undiagnosed skin lesion.

Do not use if

  • Active or suspected skin malignancy in the treated area — pro-angiogenic and pro-migratory signalling is the wrong thing to add there.

Combining it

  • synergyghk-cu-topical — The classic post-procedure repair pairing.
  • redundanttb-500 — TB-500 is a fragment of this peptide; running both is redundant.

What to monitor

  • · Track healing time and post-inflammatory erythema after procedures.
  • · Fixed-area photographs for any hair application.

Legal status

Not approved as a drug or established as a cosmetic ingredient; sold as a research chemical. Banned in sport under WADA S2.

References

  • Philp et al. 2004, thymosin beta-4 promotes angiogenesis, wound healing and hair follicle development (preclinical)
  • Goldstein & Kleinman, thymosin beta-4 in tissue repair (review) (review)

Mechanism in depth

Thymosin beta-4 is the major intracellular G-actin sequestering protein in mammalian cells, and everything else it does follows from that. Cells crawl by polymerising actin at the leading edge, and to do that they need a large pool of monomeric G-actin held in reserve, ready but not polymerising. Tbeta4 binds G-actin one-to-one and maintains that pool. When a cell needs to move, releasing sequestered actin gives it the material. This is why a single small protein has effects that look scattered across wound healing, angiogenesis, hair growth and cardiac repair — they are all cell migration problems. In hair specifically, Philp and colleagues at NIH showed in 2004 that Tbeta4 increases hair growth by activating hair follicle stem cells in the bulge region, and followed up in 2007 showing the effect runs through stem cell migration and differentiation. In wound models it accelerates keratinocyte and endothelial migration, promotes angiogenesis and reduces fibrosis — that last one is unusual, because most pro-healing signals also promote scarring, and Tbeta4 does not. The clinical development, though, went in an entirely different direction: the substantial human trials of Tbeta4 are ophthalmic, as RGN-259 eye drops. Sosne's group published a phase 2 randomised trial in severe dry eye and a further placebo-controlled phase 2 using the controlled adverse environment model. Those are real, published, randomised human trials — of eye drops. There is no human trial of topical Tbeta4 for hair or for facial skin, and the eye is a fundamentally different delivery situation from intact epidermis.

What usually goes wrong

Applying a 5 kDa protein to intact skin and expecting anything. This is the most common and most expensive error with this compound, and it is a physics problem rather than a biology problem. If you are using it, use it in the window where the barrier is open. Second, sterility: post-procedure skin with open microchannels is an infection risk and people reconstitute research-grade lyophilised powder in non-sterile conditions and apply it to it. Use bacteriostatic or sterile water, work clean, and discard early. Third, the pro-angiogenic and pro-migratory profile near an undiagnosed lesion — those are exactly the properties you do not want to add to something you have not had looked at. Fourth, anyone drug tested in sport: thymosin beta-4 is on the WADA prohibited list under S2 at all times, and post-procedure open-skin application is not obviously a zero-absorption route.

Pharmacokinetics

Bioavailability
0%
Crosses blood-brain barrier
partial
Metabolism
Cleaved by proteases into fragments, one of which — the seven-residue actin-binding motif LKKTETQ — is itself bioactive and is the basis of several derivative compounds. TB-500, sold widely as a research chemical, is marketed as a fragment of this molecule.
Elimination
No meaningful systemic exposure from intact-skin topical use. From open post-procedure skin, systemic absorption is possible and unmeasured, which matters for anyone drug tested — thymosin beta-4 is prohibited under WADA S2 at all times.

Receptor targets

  • G-actin (monomeric actin) — Binds G-actin in a 1:1 complex; this is the primary and best-characterised interaction

    Maintains the sequestered actin monomer pool that cells draw on for directed migration.

  • Hair follicle bulge stem cells — Not a direct receptor interaction

    Activation, migration and differentiation of follicular stem cells in mouse models — the basis of the hair claim.

  • Endothelial cell migration and angiogenesis — Downstream of cytoskeletal effects

    Pro-angiogenic. This is also the property that makes it a bad idea near an undiagnosed lesion.

  • Fibrosis and TGF-beta-driven scarring — Indirect

    Reduces scarring while accelerating closure, which is the unusual combination that makes it attractive post-procedure.

Trials

  • Sosne, Dunn & Kim phase 2 randomised trial of thymosin beta-4 in severe dry eye (Cornea) Phase 2 randomised · 2015

    Significant improvement in signs and symptoms of severe dry eye. This is the substantial human evidence for the molecule, and it is ophthalmic — not skin, not hair.

  • Sosne & Ousler phase 2 randomised placebo-controlled trial of thymosin beta-4 ophthalmic solution using the controlled adverse environment model (Clinical Ophthalmology) Phase 2 randomised placebo-controlled · 2015

    Dry eye signs and symptoms in a controlled adverse environment chamber. Again ophthalmic.

What to expect, and when

Post-procedure healing: days. Reduced erythema and faster re-epithelialisation over three to seven days is what the wound biology predicts and what users report. Hair: no human timeline exists, and any follicular effect would run on the hair cycle at three to six months minimum. Given that intact scalp will not admit the molecule, be sceptical of any reported hair result that did not involve dermarolling.

Stacking and comparisons

GHK-Cu immediately post-microneedling is the classic pairing and it is the one context where both compounds have a coherent delivery story, because the barrier is open. Keep it sterile and preservative-free — anything you put through open channels needs to be, and cosmetic-grade serums with fragrance and preservatives cause granulomatous reactions when pushed into dermis. TB-500 is redundant; it is marketed as a fragment of this molecule and running both makes no sense. The important non-stacking point is timing: post-procedure use is a five to seven day course while the barrier is repairing, not an indefinite protocol, because after the barrier closes nothing is getting in.

Against GHK-Cu for post-procedure repair, GHK-Cu is a fraction of the size, has an actual randomised human trial after CO2 laser resurfacing, and costs far less. On evidence and on physics, GHK-Cu is the better post-procedure choice. Against TB-500, TB-500 is sold as a fragment of this and is cheaper; neither has human skin data. Against PTD-DBM for hair, both are preclinical-only, and PTD-DBM at least was designed for topical scalp use whereas this was not. The strongest thing that can be said for Tbeta4 is that it is the only compound in this class other than botulinum toxin with genuine randomised phase 2 human trials behind it — for a completely different indication, in a completely different tissue.

Rough cost

$50–$200/month. Research-chemical vials of 2-10 mg run roughly $30-90 each. Post-procedure courses use small amounts; anecdotal daily scalp use consumes far more. Wide range because vendor pricing and purity are unstandardised. Market observation, not a sourced pricing study.

Genuinely uncertain

  • There is no human trial of topical thymosin beta-4 for hair or for facial skin. All the skin and hair data are mouse and cell culture.
  • The hair follicle stem cell activation result has not been replicated in humans.
  • How much of a 5 kDa peptide actually enters post-microneedling skin, and for how long the channels stay open, has not been quantified for this molecule.
  • The 43-residue sequence was not resolved in this session.
  • The molecular weight of 4963.4 Da in the Core record is consistent with the published mass of thymosin beta-4 but was not confirmed against a primary source in this session.
  • The plasma half-life of one to two hours is quoted for intravenous administration and I could not resolve it to a primary source.
  • Research-chemical material is unassayed, and a 43-residue peptide is far more likely to contain truncated and misfolded species than a tripeptide.

Papers